Abbott in first for Rapamune monitoring test:
This article was originally published in Clinica
Abbott Laboratories has launched what is claimed to be the first commercialised automated assay for the potent immunosuppressive drug, Rapamune. The IMx sirolimus assay, which has been released in all major countries except the US, where FDA clearance is pending, was developed by Anglo-Norwegian firm Axis-Shield. Axis will manufacture the test in its Dundee, Scotland facility. Rapamune, made by Wyeth, is indicated for the prophylaxis of organ rejection in patients receiving renal transplants. Availability of the test will facilitate monitoring of sirolimus levels in transplant patients, which have to be properly maintained in each patient to optimise response, and may also encourage wider prescription of the drug in patients who may benefit from it, said Axis-Shield.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.